Telehealth provider Hims & Hers announced it will sell a compounded version of Novo Nordisk’s recently approved Wegovy pill, triggering a public clash with Novo and raising immediate legal and regulatory questions. Novo said it would consider litigation and described Hims’ product as an "unapproved, inauthentic" copy; legal analysts noted hurdles to a straightforward infringement win because compounding laws and patent scopes can complicate enforcement. The dispute adds a commercial front to the broader GLP‑1 market fight as manufacturers, telehealth platforms, and compounders jockey for market share in the fast-growing obesity treatment segment. Industry watchers said the episode highlights how quickly new oral GLP‑1 launches can spur copycat and compounded offerings, and why brand owners are prepared to deploy both legal and regulatory routes to protect market exclusivity. Clarification: compounding refers to pharmacists preparing individualized drug formulations; commercial-scale mass-marketing of compounded versions can trigger enforcement if it skirts approvals or patents.